If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

Most patients with prostate cancer undergoing treatment experience complications associated with worse quality of life or new health risks. Prostate cancer surgery and radiation therapy are associated ...

Receiving radiotherapy after prostatectomy does negatively affect long-term health-related quality of life, including sexual function, urinary incontinence, and urinary irritation, but the timing of ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

If you have prostate cancer and radiation therapy is an option, how to choose which type is right for your situation? The answer lies in a discussion with your doctor about the pluses and minuses of ...

SpaceOAR Hydrogel reduces radiation exposure to the rectum, minimizing bowel-related side effects in prostate cancer patients undergoing radiation therapy. A study showed a 25% reduction in bowel ...

Prostate cancer stands as a significant health concern for men, emphasizing the paramount need for a comprehensive understanding of the available treatment options. Thanks to continuous advancements ...

At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.